Pulmonx outlines 2026 revenue target of $90M-$92M with cost realignment and renewed U.S. sales focus (NASDAQ:LUNG)

Management View - Pulmonx Corporation's CEO Glendon French emphasized a strategic bottom-up approach to evaluate the business, focusing on enhancing successful elements and addressing underperforming areas while realigning spending [2] - The company has set a revenue target of $90 million to $92 million for 2026, indicating a clear financial goal as part of its renewed focus on U.S. sales [2] - The management's approach reflects a commitment to operational efficiency and targeted growth strategies in the competitive healthcare market [2]